Calidi Biotherapeutics (NYSE:CLDI) Trading Up 4.1% – Here’s What Happened

Calidi Biotherapeutics, Inc. (NYSE:CLDI) shot up 4.1% during trading on Thursday . The company traded as high as $1.30 and last traded at $1.26. 495,336 shares changed hands during mid-day trading, a decline of 77% from the average session volume of 2,139,222 shares. The stock had previously closed at $1.21.

Calidi Biotherapeutics Price Performance

The stock has a 50-day moving average of $1.20 and a 200 day moving average of $1.37.

Institutional Trading of Calidi Biotherapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in CLDI. Millennium Management LLC lifted its position in Calidi Biotherapeutics by 35.5% during the fourth quarter. Millennium Management LLC now owns 136,137 shares of the company’s stock valued at $157,000 after purchasing an additional 35,637 shares during the period. Jane Street Group LLC purchased a new position in shares of Calidi Biotherapeutics during the 4th quarter valued at about $38,000. Geode Capital Management LLC lifted its holdings in shares of Calidi Biotherapeutics by 304.0% in the 4th quarter. Geode Capital Management LLC now owns 160,018 shares of the company’s stock valued at $184,000 after buying an additional 120,406 shares during the period. Virtu Financial LLC acquired a new position in shares of Calidi Biotherapeutics in the 4th quarter valued at about $84,000. Finally, RS Crum Inc. acquired a new stake in Calidi Biotherapeutics during the fourth quarter worth about $47,000. Institutional investors and hedge funds own 12.53% of the company’s stock.

Calidi Biotherapeutics Company Profile

Calidi Biotherapeutics, Inc, a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors.